TTRX · Turn Therapeutics Inc.
$12.69
-0.69 (-5.16%)
At close · Sep 11
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that the accompanying unaudited condensed consolidated interim financial statements as of June 30, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$378.01M
Shares
29.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.69
Open$13.30
Day$12.63–14.25
Available close range$2.71–13.75
Avg vol 30d76K
Short int133K · 0.4% float · 3.2d
Short vol49%
DataOct 2025–Sep 2026
Filing10-Q · Aug 12
The closing range uses available history since Oct 8, 2025; less than a full year is stored.
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$8.45M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$3.89M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.4%
Latest settlement · 3.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+130%
above
Price vs 50-day avg
+31%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
90%
near high
Momentum
relative strength
1-month return
+29%
trailing
6-month return
+269%
trailing
YTD return
+222%
this year
Relative strength
+251%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+45% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.45% of float · ▲ +15.6% MoM · 3.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
29 holders — 13F breadth
Squeeze score
63
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
112%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
8.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+130%
Bullish
Price vs 50-day avg
+31%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
90%
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $10 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+45% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.45% of float · ▲ +15.6% MoM · 3.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
29 holders — 13F breadth
Price context
position in its available closing range
Range low $3
Now $13 · 90%
Range high $14
vs 200-day avg +130%
vs 50-day avg +31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TTRX
this stock
Turn Therapeutics Inc.
|
$378.01M | +222.1% | — | — | 0.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TTRX | +26.0% | +28.7% | +268.9% | +32.2% | +222.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +27.2% | +30.5% | +251.1% | +32.6% | +210.0% |